Edmonds Duncan Registered Investment Advisors LLC Boosts Stock Position in Eli Lilly and Company (NYSE:LLY)

Edmonds Duncan Registered Investment Advisors LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 6.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 849 shares of the company’s stock after buying an additional 55 shares during the quarter. Edmonds Duncan Registered Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $660,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Simon Quick Advisors LLC boosted its stake in Eli Lilly and Company by 10.5% in the fourth quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after acquiring an additional 278 shares in the last quarter. Independent Advisor Alliance boosted its stake in shares of Eli Lilly and Company by 1.7% during the fourth quarter. Independent Advisor Alliance now owns 32,269 shares of the company’s stock worth $18,810,000 after buying an additional 544 shares during the period. Apexium Financial LP boosted its stake in shares of Eli Lilly and Company by 1,819.1% during the fourth quarter. Apexium Financial LP now owns 11,438 shares of the company’s stock worth $6,667,000 after buying an additional 10,842 shares during the period. Clear Harbor Asset Management LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $363,000. Finally, Terril Brothers Inc. lifted its position in Eli Lilly and Company by 113.2% in the fourth quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock valued at $471,000 after purchasing an additional 429 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 194,978 shares of the company’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $885.91, for a total transaction of $172,732,959.98. Following the completion of the sale, the insider now directly owns 97,583,810 shares of the company’s stock, valued at $86,450,473,117.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, major shareholder Lilly Endowment Inc sold 194,978 shares of the company’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $885.91, for a total value of $172,732,959.98. Following the transaction, the insider now owns 97,583,810 shares in the company, valued at approximately $86,450,473,117.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the transaction, the chief accounting officer now owns 7,130 shares in the company, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 849,894 shares of company stock valued at $727,475,118. 0.13% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of analyst reports. Jefferies Financial Group increased their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Bank of America reiterated a “buy” rating and issued a $1,000.00 price target on shares of Eli Lilly and Company in a report on Monday, June 24th. Truist Financial reiterated a “buy” rating and issued a $1,000.00 price objective (up previously from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Argus raised their price objective on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. Finally, Citigroup raised their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $812.72.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $906.71 on Wednesday. Eli Lilly and Company has a twelve month low of $434.34 and a twelve month high of $916.83. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The company has a market capitalization of $861.75 billion, a price-to-earnings ratio of 133.54, a PEG ratio of 1.97 and a beta of 0.41. The firm has a 50-day moving average of $818.06 and a two-hundred day moving average of $743.26.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the prior year, the company earned $1.62 EPS. Eli Lilly and Company’s revenue was up 26.0% on a year-over-year basis. As a group, analysts expect that Eli Lilly and Company will post 13.76 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.